Part of UT Health San Antonio

You are here

Gangadhara Reddy Sareddy, PhD

Contact

210-567-4912

sareddy@uthscsa.edu

For administrative calls, please contact:

Departments & Divisions

Department of Obstetrics & Gynecology
Division of Reproductive Research

Institutes and Centers

Gangadhara R Sareddy, Ph.D.

Assistant Professor

 

Dr. Gangadhara Sareddy is currently employed at The University of Texas Health at San Antonio, in the Department of Obstetrics and Gynecology. He attended Sri Krishnadevaraya University (India) and received his Bachelor's degree in Biology, followed by a Master's degree in Biochemistry. He received his Ph.D. in Animal Sciences from the University of Hyderabad (India). Dr. Sareddy studies are focused on hormonal signaling and epigenetic mechanisms in glioblastoma and gynecologic malignancies. Dr. Sareddy's current research interests include 1) studying the tumor suppressor functions of estrogen receptor beta signaling in ovarian cancer progression and therapy resistance 2) understanding the significance of histone lysine demethylase KDM1A and nuclear receptor signaling in glioma stem cells and tumor hypoxia.

  • Professional Background

    Education

    • 2010 - Doctor of Philosophy - Animal Sciences (Cancer Biology) - University of Hyderabad, India
    • 2005 - Master of Science - Biochemistry - Sri Krishnadevaraya University, India

    Training

    • 2015 - Post Doctoral Training - Cancer Biology - The University of Texas Health San Antonio

    Highlights

     

    2011:              AACR Scholar-in-Training Award, Susan G. Komen for the Cure

    2013:              Meritorious Young Scientist Award, American Association of Indian Scientists

                           in Cancer Research (AAISCR)

    2017:             Minority-serving Institution Faculty Scholar in Cancer Research Award, AACR

    2018:             Minority-serving Institution Faculty Scholar in Cancer Research Award, AACR

    2019:             Research Rising Superstar, Long School of Medicine, UTHSA

    Appointments

    • 2016 - Assistant Professor - University of Texas Health San Antonio
    • 2018 - Faculty Member - Graduate School of Biomedical Sciences - University of Texas Health San Antonio
    • 2018 - Member- CDP program- Mays Cancer Center - University of Texas Health San Antonio

  • Instruction & Training

    • 2019-Present, CSBL 6015-2 Selective Topics in Oncology: Gynecological Cancers, University of Texas Health San Antonio
    • 2019-Present, Co-Course Director, IBMS 7010-3 Cancer Biology Student Journal Club and Research Presentation , University of Texas Health San Antonio

  • Research & Grants

    1. Max and Minnie Tomerlin Voelcker Fund Young Investigator Grant                       

    2. American Cancer Society- 32931-RSG-18-187 -Research Scholar Grant                   

    3. R01 NS106173-01A1- NIH/NINDS

     

  • Service

    National Service

    Grant Reviewer

    2019: DoD-CDMRP-BCRP-Review Panel

    2020: National Science Foundation (NSF)

    Global

     

    2019-present: Associate Editor, BMC Cancer

     

     

  • Publications

    1. Sareddy GR, Challa S, Panigrahi M, Babu PP.  Wnt/beta-catenin/tcf signaling pathway activation in malignant progression of rat gliomas induced by transplacental N-ethyl-N-nitrosourea exposure. Neurochem. Res. 34:1278-88, 2009. PMID: 19148749.
    2. Sareddy GR, Panigrahi M, Challa S, Mahadevan A, Babu PP. Activation of Wnt/beta-catenin/tcf signaling pathway in human astrocytomas. Neurochem. Int. 55:307-17, 2009. PMID: 19576519.
    3. Kesanakurti D*, Sareddy GR*, Babu PP, Kirti PB. Mustard NPR1, a mammalian IkappaB homologue inhibits NF-kappaB activation in human GBM cell lines. Biochem. Biophys. Res. Commun. 390:427-433, 2009. PMID: 19766095 * Equal first author contribution.
    4. Rao AS, Reddy SG, Babu PP, Reddy AR. Antioxidant and anti-proliferative activities of navara rice bran extract. BMC Complement. Altern. Med. 10:4, 2010. PMCID: PMC2823621.
    5. Srilaxmi P, Sareddy GR, Kishor PB, Setty OH, Babu PP. Protective efficacy of natansnin, a dibenzoyl glycoside from Salvinia natans against CCl4 induced oxidative stress and cellular degeneration in rat liver. BMC Pharmacol. 10:13, 2010. PMCID: PMC2967507.
    6. Gonugunta VK, Nair BC, Rajhans R, Sareddy GR, Nair SS, Vadlamudi RK. Regulation of rDNA transcription by proto-oncogene PELP1. PLoS ONE 6(6): e21095, 2011. PMCID: PMC3113909.
    7. Sareddy GR, Geeviman K, Ramulu C, Babu PP. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway. J. Neurooncol. 106:99-110, 2012. PMID: 21847707.
    8. Sareddy GR, Geeviman K, Panigrahi M, Challa S, Mahadevan A, Babu PP. Increased β-catenin/Tcf signaling in pilocytic astrocytomas: a comparative study to distinguish pilocytic astrocytomas from low-grade diffuse astrocytomas. Neurochem. Res. 37:96-104, 2012. PMID: 21922255.
    9. Zhang QG, Wang RM, Scott E, Han D, Dong Y, Tu JY, Yang F, Reddy Sareddy G, Vadlamudi RK, Brann DW. Hypersensitivity of the hippocampal CA3 region to stress-induced neurodegeneration and amyloidogenesis in a rat model of surgical menopause. Brain. 136:1432-1445, 2013. PMCID: PMC3634196.
    10. Sareddy GR, Vadlamudi RK. Emerging significance of estrogen receptor β in gliomas. J. Cancer Sci. Ther. 5: e121, 2013.
    11. Sareddy GR, Nair BC, Gonugunta VK, Zhang QG, Brenner AJ, Brann DW, Tekmal RR, Vadlamudi RK. Therapeutic significance of estrogen receptor β agonists in gliomas. Mol. Cancer Ther. 11:1174-82, 2012. PMCID: PMC3721065.
    12. Sareddy GR*, Nair BC, Krishnan SK, Gonugunta VK, Zhang QG, Suzuki T, Miyata N, Brenner AJ, Brann DW, Vadlamudi RK*. KDM1 is a novel therapeutic target for the treatment of gliomas. Oncotarget 4:18-28, 2013. PMCID: PMC3702204.*Corresponding author
    13. Sareddy GR, Kesanakurti D, Kirti PB, Babu PP. Novel antiproliferative and antioxidant role of BjAnn1, a mustard annexin protein in human glioblastoma cell lines. J. Cancer Sci. Ther. 5:256-253, 2013.
    14. Sareddy GR, Kesanakurti D, Kirti PB, Babu PP. Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/β-catenin/Tcf signaling pathway in human glioblastoma cells. Neurochem. Res. 38:2313-2322, 2013. PMID: 24013885.
    15. Zhang QG, Wang R, Tang H, Dong Y, Chan A, Sareddy GR, Vadlamudi RK, Brann DW. Brain-Derived Estrogen Exerts Anti-inflammatory and Neuroprotective Actions in the Rat Hippocampus. Mol. Cell Endocrinol. 389:84-91, 2014. PMCID: PMC4040313.
    16. Gonugunta V, Sareddy GR, Krishnan SR, Cortez V, Saha Roy S, Tekmal RR, Vadlamudi RK. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance. Mol. Cancer Ther. 13:1578-88, 2014. PMCID: PMC4226651.
    17. Nair BC, Krishnan SR, Sareddy GR, Mann M, Xu B, Natarajan M, Hasty P, Brann D, Tekmal RR, Vadlamudi RK. Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA Damage Response. Cell Death. Differ. 21:1409-18, 2014. PMCID: PMC4131173.
    18. Gonugunta VK, Miao L, Sareddy GR, Ravindranathan P, Vadlamudi R, Raj GV. The social network of PELP1 and its implications in breast and prostate cancers. Endocr. Relat. Cancer 21:T79-86, 2014. PMID: 24859989.
    19. Krishnan SR, Nair BC, Sareddy GR, Saha Roy S, Natarajan M, Suzuki T, Peng Y, Raj G, and Vadlamudi RK. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing TNBC cells. Breast Cancer Res. Treat. 150:487-99, 2015. PMCID: PMC4385448.
    20. Sareddy GR, Vadlamudi RK. Cancer therapy using natural ligands that target estrogen receptor beta. Chin. J Nat. Med. 13:801-7, 2015. PMCID: PMC4896163.
    21. Sareddy GR, Zhang Q, Wang R, Scott E, Zou Y, O’Connor JC, Chen Y, Dong Y, Vadlamudi RK, Bran D. Proline-, glutamic acid-, and leucine rich protein-1 mediates estrogen rapid signaling and neuroprotection in the brain. Proc. Natl. Acad. Sci. USA. 112:E6673-82, 2015. PMCID: PMC4672783.
    22. Sareddy GR, Vadlamudi RK. PELP1: Structure, biological function and clinical significance. Gene. 585:128-34, 2016. PMCID: PMC4838531.
    23. Sareddy GR, Li X, Liu J, Viswanadhapalli S, Garcia L, Gruslova A, Cavazos D, Garcia M, Strom AM, Gustafsson JA, Tekmal RR, Brenner A, Vadlamudi RK. Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Sci. Rep. 6:24185, 2016. PMCID: PMC4850367.
    24. Yuan B, Cheng L, Gupta K, Chiang H, Gupta H, Sareddy GR, Wang D, Lathrop K, Elledge R, Wang P, McHardy S, Vadlamudi R, Curiel TJ, Hu Y, Ye Q, Li R. Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer. Oncotarget. 7:42585-42597, 2016. PMCID: PMC5173158.
    25. Thakkar R, Wang R, Sareddy G, Wang J, Thiruvaiyaru D, Vadlamudi R, Zhang Q, Brann D. NLRP3 Inflammasome Activation in the Brain after Global Cerebral Ischemia and Regulation by 17β-Estradiol. Oxid Med Cell Longev. 2016:8309031, 2016. PMCID: PMC5097821.
    26. Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, Liu Y, Turk MJ, Thedieck K, Hurez V, Li R, Vadlamudi R, Curiel TJ. Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. Cancer Res. 76:6964-6974, 2016. PMCID: PMC5228566.
    27. Sareddy GR*, Viswanadhapalli S, Surapaneni P, Suzuki T, Brenner A, Vadlamudi RK. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response (UPR) pathway. Oncogene. 36:2423-2434, 2017. PMCID: PMC5526658.*Corresponding author
    28. Gupta H, Clark C, Yuan B, Sareddy G, Pandeswara S, Padron A, Hurez V, Vadlamudi R, Li R, Conejo-Garcia J, Curiel T. Tumor cell intrinsic PD-L1 promotes tumor initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduct. Target. Ther. 1, 16030. 2017. PMCID: PMC5547561.
    29. Thakkar R, Sareddy GR, Zhang Q, Wang R, Vadlamudi RK, Brann D. PELP1 - A Key Mediator of Estrogen Signaling and Actions in the Brain. J Neuroendocrinol. 2017, doi: 10.1111/jne.12484. PMCID: PMC5785553.
    30. Liu J, Viswanadhapalli S, Garcia L, Zhou M, Nair BC, Kost E, Tekmal RR, Li R, Rao MK, Curiel T, Vadlamudi RK, Sareddy GR*. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer. Oncotarget. 8:50002-50014, 2017. PMCID: PMC5564823.*Corresponding author.
    31. Raj GV, Sareddy GR, Ma S, Lee TK, Viswanadhapalli S, Li R, Liu X, Murakami S, Chen CC, Lee WR, Mann M, Krishnan SR, Manandhar B, Gonugunta VK, Strand D, Tekmal RR, Ahn JM, Vadlamudi RK. Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers. Elife. 6. pii: e26857, 2017. PMCID: PMC5548489.
    32. Liu J*, Sareddy GR*, Zhou M, Viswanadhapalli S, Li X, Lai Z, Tekmal RR, Brenner AJ, Vadlamudi RK. Differential effects of estrogen receptor beta isoforms on glioblastoma progression. Cancer Res. 78:3176-3189, 2018. PMCID: PMC6004261.*Equal first author contribution.
    33. Lu Y*, Sareddy G*, Wang J, Wang R, Li Y, Dong Y, Zhang Q, Liu J, OConnor J, Xu J, Vadlamudi RK, Brann D. Neuron-Derived Estrogen Regulates Synaptic Plasticity and Memory. J Neuro Sci. 2019. pii: 1970-18.  PMID: 30728170.*Equal first author contribution.
    34. Zhou M, Sareddy GR, Li M, Liu J, Luo L, Pitta Venkata P, Viswanadhapalli S, Tekmal RR, Brenner A, and Vadlamudi1 RK.  Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.  Sci. Rep. 9:6124, 2019. PMID: 30992459.
    35. Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Ma S, Sonavane R, Pratap UP, Altwegg KA, Li X, Chang A, Riveros AC, Dileep KV, Zhang KYJ, Pan X, Murali R, Bajda M, Raj GV, Brenner AJ, Manthati V, Rao MK, Tekmal RR, Nair HB, Nickisch KJ, Vadlamudi RK. EC359-A first-in-class small molecule inhibitor for targeting oncogenic LIFR signaling in triple negative breast cancer. Mol Cancer Ther. 18:1341-1354, 2019. PMID: 31142661.
    36. Viswanadhapalli S, Ma S, Sareddy GR, Lee TK, Li M, Gilbreath C, Liu X, Luo Y, Pratap UP, Zhou M, Blatt EB, Kassees K, Arteaga C, Alluri P, Rao M, Weintraub ST, Tekmal RR, Ahn JM, Raj GV, Vadlamudi RK. Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers. Breast Cancer Res. 21:150, 2019. PMID: 31878959.
    37. Sareddy GR, Pratap UP, Viswanadhapalli S, Pitta Venkata P, Nair BC, Krishnan SR, Zheng S, Gilbert AR, Brenner AJ, Brann DW, Vadlamudi RK. PELP1 promotes glioblastoma progression by enhancing Wnt/β-catenin signaling. Neuro-Oncology Advances. Neuro Oncol Adv, 1: vdz001, 2019. PMID: 32309805.
    38. Luo Y, Li M, Pratap PP, Viswanadhapalli S, Liu J, Pitta Venkata P, Altwegg KA, Palacios BE, Li X, Chen Y, Rao MK, Brenner AJ, Sareddy GR* Vadlamudi RK*. PELP1 signaling contributes to medulloblastoma progression by regulating NF-κB pathway. Mol Carcinog, 59:281-292, 2019.  PMID: 31872914.*Corresponding author.
    39. Lu Y, Sareddy G, Wang J, Zhang Q, Tang F, Pratap U, Tekmal R, Vadlamudi R, Brann D. Neuron-Derived Estrogen is Critical for Astrocyte Activation and Neuroprotection of the Ischemic Brain. J Neuro Sci. 2020 (in press).